The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare negotiation.

CMS listed Ozempic, Rybelsus and Wegovy — all forms of semaglutide — at the top of the list of drugs for which Medicare will the negotiate the price of in 2025. The list price for a one-month supply of Ozempic costs close to $1,000 without insurance or manufacturer coupons.

According to CMS data, Medicare Part D spending on Ozempic was more than $4.6 billion in 2022.

Ozempic has become emblematic of the explosive enthusiasm for GLP-1 medications in the........

© The Hill